At 72 weeks, participants using Zepbound saw an average weight-loss reduction of 20.2% versus 13.7% with Novo Nordisk’s own ...

A larger waist circumference is associated with a higher risk of all-cause mortality and decreased life expectancy. Meanwhile ...

Eli Lilly's Zepbound surpassed Novo Nordisk's Wegovy in reducing waist circumference and overall weight loss in a recent ...

Eli Lilly said on Sunday its drug Zepbound was superior to Novo Nordisk's Wegovy across five weight-loss targets such as ...

Clinical trial participants who took tirzepatide, the drug sold as Zepbound, lost an average of 50 pounds (22.8 kilograms) ...

Shares in British meat producer Cranswick slumped about 9% on Monday after UK supermarkets suspended supplies from one of its ...

Britain's Virgin Media O2 said it was combining its enterprise unit with business-to-business telecoms provider Daisy Group ...

The trends worry health experts, who say the medicines have potential to narrow differences in obesity rates among ...

Eli Lilly and Co's obesity drug Zepbound led to greater weight loss than Novo Nordisk's Wegovy in a head-to-head Phase 3b ...

Eli Lilly announced that its obesity drug Zepbound outperformed Novo Nordisks Wegovy in a direct comparison across five key ...

President Donald Trump says he'll sign an executive order on Monday that, if implemented, could bring down the costs of some ...